Hims and Hers just shut down its dermatology business after stock slump on FDA's weight-loss drug decisionBusiness Insider • 03/07/25
Hims & Hers: The Odds Are In Your Favor, Here's How To Take Advantage (Rating Upgrade)Seeking Alpha • 03/07/25
Hims & Hers Stocks Sinks Despite Huge Revenue Growth. Is This a Buying Opportunity in the Stock?The Motley Fool • 03/01/25
Behind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats UpInvestors Business Daily • 02/28/25
HIMS Stock Declines Following Q4 Earnings Miss, Gross Margin ContractsZacks Investment Research • 02/25/25
Novo Nordisk's stock is rallying as Hims & Hers' stock falters. An Ozempic alternative won't be available for long.Market Watch • 02/25/25
Hims & Hers: Capitalizing On The GLP-1 Rush Before The Window Closes (Rating Upgrade)Seeking Alpha • 02/25/25